Switzerland· 66040002
Qtern, Filmtabletten
A saxagliptin and dapagliflozin product containing dapagliflozinum, saxagliptinum, registered in Switzerland by AstraZeneca AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Saxagliptin and dapagliflozin is registered in 11 of 19 countries.
Countries holding a registration under ATC A10BD21 (saxagliptin and dapagliflozin), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Saxagliptin and dapagliflozin · ATC A10BD21
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- dapagliflozinum, saxagliptinum
- Manufacturer
- AstraZeneca AG
- Country
- Switzerland (CH)
- ATC code
- A10BD21
- ATC class
- Saxagliptin and dapagliflozin
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768066040002598 StkCHF 280.7
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Saxagliptin and dapagliflozin in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainQTERN 5 MG/10 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- United KingdomQtern 5mg/10mg tabletsAstraZeneca UK Ltd
- IrelandQtern 5 mg/10 mg film-coated tabletsAstraZeneca AB
- IcelandQternAstraZeneca AB*
- NetherlandsQtern, filmomhulde tablettenAstraZeneca AB
- PolandQternAstraZeneca AB
- SwedenQtern 5 mg/10 mg Filmdragerad tablettAstraZeneca AB
- United StatesDAPAGLIFLOZIN AND SAXAGLIPTINNovadoz Pharmaceuticals LLC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Qtern
- Liechtenstein · Qtern
- Norway · Qtern
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e1b8ef76-7ff4-4cd6-b9e0-68b1296c6b73 GET /v1/drugs/e1b8ef76-7ff4-4cd6-b9e0-68b1296c6b73?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "saxagliptinum 5 mg + dapagliflozinum 10 mg",
"valid_from": "2017-08-01",
"limitations": "[{\"description\":\"Zur Behandlung von erwachsenen Patienten mit einem Typ 2 Diabetes mellitus zur Verbesserung der glykämischen Kontrolle:<br>\\nIn Kombination mit Metformin zusammen mit Diät und körperlicher Aktivität, wenn mit Diät und körperlicher Aktivität in Kombination mit Metformin und 10 mg Dapagliflozin keine ausreichende Blutzuckerkontrolle erreicht wird oder wenn bereits mit der Kombination aus 10 mg Dapagliflozin und 5 mg Saxagliptin als separate Tabletten behandelt wird.<br>\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2017-08-01\"}]",
"galenic_form": "Filmtabl 5 mg/10 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2017-08-01",
"self_retention_pct": 10
}See everything about saxagliptin and dapagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.